drugset / Trial / NCT07567781

A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.

NCT07567781

Phase 1 Active not recruiting 12 enrolled AbbVie
NaSingle-groupOpen-labelBasic science

Summary

The objective of this study is to assess the effect of repeated doses of ABBV-722 on the single dose pharmacokinetics (PK) of Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin

Timeline

Start
2026-04-30
Primary completion
2026-07
Completion
2026-07

Drugs

EvaluationDrugModalityDoseRoute
Subject ABBV-722 Unknown Oral
Subject Digoxin Other / unclassified Oral
Subject Metformin Small molecule Oral
Subject Midazolam Small molecule Oral
Subject Pitavastatin Small molecule Oral
Subject Sitagliptin Small molecule Oral

Indications

No indication recorded.